From cancer to diabetes: Singapore biomedical startups expand into China to accelerate development of new treatments
Full story
Biomedical startups from Singapore are expanding their operations into China. These companies aim to accelerate the development of treatments for conditions such as cancer and diabetes. They are utilizing China's large patient population and hospital networks. The startups are also using Chinese manufacturing capabilities. However, they must manage changing regulations in the country.
Singapore startups are tapping China’s vast patient pool, hospital networks and manufacturing capabilities, but they must also navigate its evolving regulatory landscape.